CLLS logo

Cellectis S.A. American Depositary Shares

CLLS

CLLS: Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

more

Show CLLS Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of CLLS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CLLS's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells Jul. 04, 2023
  • Patent Title: Universal chimeric antigen receptor t cells specific for cd22 Jul. 04, 2023
  • Patent Title: Compact scaffold of cas9 in the type ii crispr system Jun. 27, 2023
  • Patent Title: Sequential gene editing in primary immune cells Jun. 13, 2023
  • Patent Title: Canola with high oleic acid Apr. 11, 2023
  • Patent Title: Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy Mar. 14, 2023
  • Patent Title: Mutant Feb. 14, 2023
  • Patent Title: Method for making nicotiana plants with mutations in xylt and fuct alleles using rare-cutting endonucleases Jan. 17, 2023
  • Patent Title: Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy Nov. 15, 2022
  • Patent Title: Alfalfa with reduced lignin composition Oct. 25, 2022
  • Patent Title: Sequential gene editing in primary immune cells Oct. 11, 2022
  • Patent Title: Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells Aug. 16, 2022
  • Patent Title: Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system Jun. 21, 2022
  • Patent Title: Methods for altering amino acid content in plants through frameshift mutations Apr. 26, 2022
  • Patent Title: Methods for engineering highly active t cell for immunotherapy Apr. 26, 2022
  • Patent Title: Methods for engineering allogeneic and highly active t cell for immunotherapy Apr. 19, 2022
  • Patent Title: Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells Mar. 15, 2022
  • Patent Title: Method to overcome dna chemical modifications sensitivity of engineered tale dna binding domains Jan. 11, 2022
  • Patent Title: Method for the generation of compact tale-nucleases and uses thereof Dec. 14, 2021
  • Patent Title: Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients Nov. 30, 2021
  • Patent Title: Tale-protein scaffolds and uses thereof Oct. 05, 2021
  • Patent Title: Cd19 specific chimeric antigen receptor and uses thereof Aug. 03, 2021
  • Patent Title: Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy May. 25, 2021
  • Patent Title: Cd19 specific chimeric antigen receptor and uses thereof May. 18, 2021
  • Patent Title: Chimeric antigen receptors with integrated controllable functions Apr. 27, 2021
  • Patent Title: Cd123 specific chimeric antigen receptors for cancer immunotherapy Apr. 27, 2021
  • Patent Title: Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation Jan. 19, 2021
  • Patent Title: Cd19 specific chimeric antigen receptor and uses thereof Dec. 29, 2020
  • Patent Title: Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system Dec. 22, 2020
  • Patent Title: Modifying messenger rna stability in plant transformations Nov. 17, 2020
  • Patent Title: Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells Nov. 17, 2020
  • Patent Title: Transcription activator-like effector (tale) fusion protein Oct. 27, 2020
  • Patent Title: Method of engineering chemotherapy drug resistant t-cells for immunotherapy Oct. 27, 2020
  • Patent Title: Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment Sep. 08, 2020
  • Patent Title: Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy Sep. 01, 2020
  • Patent Title: Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy Aug. 25, 2020
  • Patent Title: Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy Aug. 25, 2020
  • Patent Title: Tevi chimeric endonuclease and their preferential cleavage sites Aug. 11, 2020
  • Patent Title: Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation Jul. 14, 2020
  • Patent Title: Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system Mar. 10, 2020
  • Patent Title: Modifying soybean oil composition through targeted knockout of the fad3a/b/c genes Feb. 04, 2020
  • Patent Title: Ror1 specific multi-chain chimeric antigen receptor Jan. 28, 2020
  • Patent Title: Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish Jan. 07, 2020
  • Patent Title: Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells Dec. 31, 2019
  • Patent Title: Potatoes with reduced cold-induced sweetening Dec. 24, 2019
  • Patent Title: Rare-cutting endonucleases for efficient and specific targeting dna sequences comprising highly repetitive motives Dec. 17, 2019
  • Patent Title: Method for modulating car-induced immune cells activity Nov. 12, 2019
  • Patent Title: Modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins Nov. 12, 2019
  • Patent Title: Use of pretalpha or functional variant thereof for expanding tcralpha deficient t cells Oct. 01, 2019
  • Patent Title: Rna based method to obtain stably integrated retroviral vectors Aug. 13, 2019
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CLLS in WallStreetBets Daily Discussion

CLLS News

Recent insights relating to CLLS

CNBC Recommendations

Recent picks made for CLLS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CLLS

Corporate Flights

Flights by private jets registered to CLLS